HudaSalmanMD

Hematology • Indianapolis, IN

Hematologic Oncology

Associate Professor, Internal Medicine, Stony Brook University School of Medicine

Join to view full profile

Dr. Salman is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Salman's full profile

Already have an account?

Office
Brown center Indiana University
Indianapolis, IN 46202

Education & Training

Montefiore Medical Center/Albert Einstein College of Medicine (Moses and Weiler Campuses)Fellowship, Hematology and Medical Oncology, 1999 - 2002
Lincoln Medical and Mental Health CenterResidency, Internal Medicine, 1996 - 1999
University of Jordan Faculty of MedicineClass of 1991

Certifications & Licensure

IN State Medical License 2021 - 2025
NY State Medical License 2015 - 2022
GA State Medical License 2013 - 2016
VA State Medical License 2011 - 2014
OH State Medical License 2009 - 2012
TN State Medical License 2005 - 2007
American Board of Internal Medicine Hematology

Clinical Trials

CD4CAR for CD4+ Leukemia and Lymphoma Start of enrollment: 2020 Jul 09
Recruiting
Phase 1
Roles: Study Chair, Contact, Sponsor-Investigator, Principal Investigator
Chimeric Antigen Receptor T Cell Therapy Redirected to CD4 (CD4CAR)as a Second Line Treatment for Chronic Myelomonocytic Leukemia, CMML. Start of enrollment: 2024 Feb 21
Recruiting
Phase 1
Roles: Principal Investigator, Sponsor-Investigator, Contact
Chimeric Antigen Receptor T Cell Redirected to Target CD4 Positive Relapsed Refractory Acute Myeloid Leukemia (AML ) as a Bridge to Allogeneic Stem Cell Transplant Start of enrollment: 2024 Mar 19
Recruiting
Phase 1
Roles: Principal Investigator, Sponsor-Investigator, Contact

Publications & Presentations

PubMed

Ancestral differences in anti-cancer treatment efficacy and their underlying genomic and molecular alterations.
Mei Luo, Jingwen Yang, Alejandro A Schaffer, Chengxuan Chen, Yuan Liu
Cancer Discovery. 2024-11-27
NCCN Guidelines® Insights: Management of Immunotherapy-Related Toxicities, Version 2.2024.
John A Thompson, Bryan J Schneider, Julie Brahmer, Mohammad Abu Zaid, Amaka Achufusi
Journal of the National Comprehensive Cancer Network. 2024-11-01
Comparative Analysis of AML Classification Systems: Evaluating the WHO, ICC, and ELN Frameworks and Their Distinctions.
Huda Salman
Cancers. 2024-08-22